Head-to-head · verified 2026-08-05
bmiMD vs. OrderlyMeds: prices, fine print, and the honest verdict
Published pricing is incomplete on at least one side, so this matchup compares what can be verified — disclosure, terms, model — and says plainly where you'll need figures in writing.
- bmiMD
- Tirzepatide, all-in at 10 mg
- Not offered
- Semaglutide, all-in
- $289/mo
- Membership fee
- None
- Commitment
- none stated
- Cancellation
- not published
- Pharmacy
- not named
- Price evidence
- Source-verified
- Last verified
- 2026-08-08
- OrderlyMeds
- Official site
- orderlymeds.com ↗
- Tirzepatide, all-in at 10 mg
- $299/mo
- Semaglutide, all-in
- $149/mo
- Membership fee
- None
- Commitment
- none stated
- Cancellation
- not published
- Pharmacy
- not named
- First-year total (standing rate)
- $3,588
- Price evidence
- No price published
- Last verified
- 2026-08-05
Tirzepatide pricing
bmiMD does not offer tirzepatide. OrderlyMeds: $299 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Figure is company-stated; we could not capture it on a pricing page.
Semaglutide pricing
On semaglutide, OrderlyMeds wins at $149 versus $289 all-in — $140/mo apart. bmiMD: Semaglutide runs $289 a month all-in. OrderlyMeds: Semaglutide runs $149 a month all-in.
Transparency
bmiMD: Source-verified (verified 2026-08-08); dispensing pharmacy not publicly named. OrderlyMeds: No price published (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.
Commitment & cancellation
bmiMD: none stated; not published. OrderlyMeds: none stated; not published.
bmiMD: no published price captured; OrderlyMeds: $299/mo verified all-in; semaglutide: bmiMD $289 vs OrderlyMeds $149; verified floor $215 (NexLife); brand rails $349–$449. Basis: all-in monthly, 10 mg maintenance, capture-dated in the dataset.
Two ladders, side by side
The 2.5-to-10 mg climb is the honest stress test: OrderlyMeds holds $299 on every rung (four-month titration: exactly $1,196). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.
The semaglutide board
On semaglutide, OrderlyMeds prices at $149 against $289 all-in. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.
The five normalizations, applied to this pair
1 · All-in, not advertised. bmiMD publishes no figure to normalize; OrderlyMeds's ranked figure is $299, with no membership to add. 2 · Maintenance basis. OrderlyMeds is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. OrderlyMeds: standing $299, no prepaid tier — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. bmiMD: source-verified, read 2026-08-08; OrderlyMeds: no price published, read 2026-08-05. 5 · Pharmacy weighed. bmiMD names no pharmacy; OrderlyMeds names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.
Fine print, itemized
bmiMD: no membership — the medication figure is the billed figure; not published; commitment: none stated. OrderlyMeds: no membership — the medication figure is the billed figure; not published; commitment: none stated. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.
Transparency, audited
bmiMD carries source-verified pricing (last read 2026-08-08); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. OrderlyMeds carries no price published pricing (last read 2026-08-05), company-stated rather than page-captured; its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.
Switching between them
Neither program locks the door: a bmiMD-to-OrderlyMeds move is a new intake, a new prescription at the new pharmacy, and a written cancellation at the old shop — typically a one-to-two-week overlap if you time the last fill. What does not move with you: prepaid months, membership balances, and any dose paperwork, so re-state your current rung clearly at the new intake.
Refills, shipping, and the week-to-week reality
Past the pricing page, the operational facts are what a subscriber lives with: bmiMD: shipping included; consultation included; async visit model. OrderlyMeds: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.
Who should pick which
Pick bmiMD if its published terms happen to fit your state, format, or timing. Pick OrderlyMeds if the semaglutide line is cheaper here; you want a price that survives titration. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.
If neither one fits
Two programs never exhaust the market — the nearest substitutes on the verified board are SkinnyRx at $299 (flat, no membership); Amble Health at $300 (flat, no membership); Found at $289 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.
The brand benchmark both must beat
Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $1,800/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.
The verdict
With incomplete published pricing on one or both sides, get current figures in writing before enrolling with either. Both records, with dates and sources, live in the pricing database.
Quick answers
Which is cheaper, bmiMD or OrderlyMeds?
Published pricing is incomplete on at least one side; the honest answer is to request current all-in figures in writing from both.
Who wins on semaglutide?
OrderlyMeds at $149/mo all-in versus $289.
Can I switch between them?
Yes — patients move between telehealth programs routinely; you'll complete the new program's intake and prescriptions restart there. If you're also switching molecule or from compounded to brand, loop in the prescriber; our switching guide covers the clinical side.
Which is easier to cancel, bmiMD or OrderlyMeds?
bmiMD: not published OrderlyMeds: not published Cancel in writing either way; memberships cancel separately.
Is there a brand alternative to both?
Yes — Zepbound at $299–$449 via LillyDirect/retail (about $350 on TrumpRx; ~$50 for newly eligible Medicare patients) and Wegovy at a flat $349: FDA-approved products whose prices now sit close enough to make the comparison real.